Industry Research Reports

Home > Reports > Medical Care > VEGF & VEGFR Inhibitor Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

VEGF & VEGFR Inhibitor Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-12

Pages: 109 Pages

Report ld: 2625228

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for VEGF & VEGFR Inhibitor Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for VEGF & VEGFR Inhibitor Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of VEGF & VEGFR Inhibitor Drugs by region & country, by Type, and by Application.

The VEGF & VEGFR Inhibitor Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VEGF & VEGFR Inhibitor Drugs.

Market Segmentation

Report Metric
Details
Report Title
VEGF & VEGFR Inhibitor Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global VEGF & VEGFR Inhibitor Drugs Companies Covered
Pfizer, Novartis AG, GlaxoSmithKline plc, Sanofi, AstraZeneca plc, Bristol-Myers-Squibb Company, Genentech, Inc. (Roche), Merck & Co., Inc., Bayer AG, Eli Lilly & Company
Global VEGF & VEGFR Inhibitor Drugs Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global VEGF & VEGFR Inhibitor Drugs Market, Segment by Type
Tyrosine Kinase Inhibitors

Monoclonal Antibodies

Others
Global VEGF & VEGFR Inhibitor Drugs Market, Segment by Application
Oncology

Ophthalmology

Others
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of VEGF & VEGFR Inhibitor Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of VEGF & VEGFR Inhibitor Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of VEGF & VEGFR Inhibitor Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 VEGF & VEGFR Inhibitor Drugs Product Introduction
    1.2 Global VEGF & VEGFR Inhibitor Drugs Market Size Forecast
    1.3 VEGF & VEGFR Inhibitor Drugs Market Trends & Drivers
        1.3.1 VEGF & VEGFR Inhibitor Drugs Industry Trends
        1.3.2 VEGF & VEGFR Inhibitor Drugs Market Drivers & Opportunity
        1.3.3 VEGF & VEGFR Inhibitor Drugs Market Challenges
        1.3.4 VEGF & VEGFR Inhibitor Drugs Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global VEGF & VEGFR Inhibitor Drugs Players Revenue Ranking (2023)
    2.2 Global VEGF & VEGFR Inhibitor Drugs Revenue by Company (2019-2024)
    2.3 Key Companies VEGF & VEGFR Inhibitor Drugs Manufacturing Base Distribution and Headquarters
    2.4 Key Companies VEGF & VEGFR Inhibitor Drugs Product Offered
    2.5 Key Companies Time to Begin Mass Production of VEGF & VEGFR Inhibitor Drugs
    2.6 VEGF & VEGFR Inhibitor Drugs Market Competitive Analysis
        2.6.1 VEGF & VEGFR Inhibitor Drugs Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by VEGF & VEGFR Inhibitor Drugs Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF & VEGFR Inhibitor Drugs as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Tyrosine Kinase Inhibitors
        3.1.2 Monoclonal Antibodies
        3.1.3 Others
    3.2 Global VEGF & VEGFR Inhibitor Drugs Sales Value by Type
        3.2.1 Global VEGF & VEGFR Inhibitor Drugs Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global VEGF & VEGFR Inhibitor Drugs Sales Value, by Type (2019-2030)
        3.2.3 Global VEGF & VEGFR Inhibitor Drugs Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Oncology
        4.1.2 Ophthalmology
        4.1.3 Others
    4.2 Global VEGF & VEGFR Inhibitor Drugs Sales Value by Application
        4.2.1 Global VEGF & VEGFR Inhibitor Drugs Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global VEGF & VEGFR Inhibitor Drugs Sales Value, by Application (2019-2030)
        4.2.3 Global VEGF & VEGFR Inhibitor Drugs Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global VEGF & VEGFR Inhibitor Drugs Sales Value by Region
        5.1.1 Global VEGF & VEGFR Inhibitor Drugs Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global VEGF & VEGFR Inhibitor Drugs Sales Value by Region (2019-2024)
        5.1.3 Global VEGF & VEGFR Inhibitor Drugs Sales Value by Region (2025-2030)
        5.1.4 Global VEGF & VEGFR Inhibitor Drugs Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        5.2.2 North America VEGF & VEGFR Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        5.3.2 Europe VEGF & VEGFR Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        5.4.2 Asia Pacific VEGF & VEGFR Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        5.5.2 South America VEGF & VEGFR Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        5.6.2 Middle East & Africa VEGF & VEGFR Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions VEGF & VEGFR Inhibitor Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions VEGF & VEGFR Inhibitor Drugs Sales Value
    6.3 United States
        6.3.1 United States VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        6.3.2 United States VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States VEGF & VEGFR Inhibitor Drugs Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        6.4.2 Europe VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe VEGF & VEGFR Inhibitor Drugs Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        6.5.2 China VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
        6.5.3 China VEGF & VEGFR Inhibitor Drugs Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        6.6.2 Japan VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan VEGF & VEGFR Inhibitor Drugs Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        6.7.2 South Korea VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea VEGF & VEGFR Inhibitor Drugs Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        6.8.2 Southeast Asia VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia VEGF & VEGFR Inhibitor Drugs Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India VEGF & VEGFR Inhibitor Drugs Sales Value, 2019-2030
        6.9.2 India VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
        6.9.3 India VEGF & VEGFR Inhibitor Drugs Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Pfizer
        7.1.1 Pfizer Profile
        7.1.2 Pfizer Main Business
        7.1.3 Pfizer VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
        7.1.4 Pfizer VEGF & VEGFR Inhibitor Drugs Revenue (US$ Million) & (2019-2024)
        7.1.5 Pfizer Recent Developments
    7.2 Novartis AG
        7.2.1 Novartis AG Profile
        7.2.2 Novartis AG Main Business
        7.2.3 Novartis AG VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
        7.2.4 Novartis AG VEGF & VEGFR Inhibitor Drugs Revenue (US$ Million) & (2019-2024)
        7.2.5 Novartis AG Recent Developments
    7.3 GlaxoSmithKline plc
        7.3.1 GlaxoSmithKline plc Profile
        7.3.2 GlaxoSmithKline plc Main Business
        7.3.3 GlaxoSmithKline plc VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
        7.3.4 GlaxoSmithKline plc VEGF & VEGFR Inhibitor Drugs Revenue (US$ Million) & (2019-2024)
        7.3.5 Sanofi Recent Developments
    7.4 Sanofi
        7.4.1 Sanofi Profile
        7.4.2 Sanofi Main Business
        7.4.3 Sanofi VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
        7.4.4 Sanofi VEGF & VEGFR Inhibitor Drugs Revenue (US$ Million) & (2019-2024)
        7.4.5 Sanofi Recent Developments
    7.5 AstraZeneca plc
        7.5.1 AstraZeneca plc Profile
        7.5.2 AstraZeneca plc Main Business
        7.5.3 AstraZeneca plc VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
        7.5.4 AstraZeneca plc VEGF & VEGFR Inhibitor Drugs Revenue (US$ Million) & (2019-2024)
        7.5.5 AstraZeneca plc Recent Developments
    7.6 Bristol-Myers-Squibb Company
        7.6.1 Bristol-Myers-Squibb Company Profile
        7.6.2 Bristol-Myers-Squibb Company Main Business
        7.6.3 Bristol-Myers-Squibb Company VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
        7.6.4 Bristol-Myers-Squibb Company VEGF & VEGFR Inhibitor Drugs Revenue (US$ Million) & (2019-2024)
        7.6.5 Bristol-Myers-Squibb Company Recent Developments
    7.7 Genentech, Inc. (Roche)
        7.7.1 Genentech, Inc. (Roche) Profile
        7.7.2 Genentech, Inc. (Roche) Main Business
        7.7.3 Genentech, Inc. (Roche) VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
        7.7.4 Genentech, Inc. (Roche) VEGF & VEGFR Inhibitor Drugs Revenue (US$ Million) & (2019-2024)
        7.7.5 Genentech, Inc. (Roche) Recent Developments
    7.8 Merck & Co., Inc.
        7.8.1 Merck & Co., Inc. Profile
        7.8.2 Merck & Co., Inc. Main Business
        7.8.3 Merck & Co., Inc. VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
        7.8.4 Merck & Co., Inc. VEGF & VEGFR Inhibitor Drugs Revenue (US$ Million) & (2019-2024)
        7.8.5 Merck & Co., Inc. Recent Developments
    7.9 Bayer AG
        7.9.1 Bayer AG Profile
        7.9.2 Bayer AG Main Business
        7.9.3 Bayer AG VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
        7.9.4 Bayer AG VEGF & VEGFR Inhibitor Drugs Revenue (US$ Million) & (2019-2024)
        7.9.5 Bayer AG Recent Developments
    7.10 Eli Lilly & Company
        7.10.1 Eli Lilly & Company Profile
        7.10.2 Eli Lilly & Company Main Business
        7.10.3 Eli Lilly & Company VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
        7.10.4 Eli Lilly & Company VEGF & VEGFR Inhibitor Drugs Revenue (US$ Million) & (2019-2024)
        7.10.5 Eli Lilly & Company Recent Developments

 8 Industry Chain Analysis
    8.1 VEGF & VEGFR Inhibitor Drugs Industrial Chain
    8.2 VEGF & VEGFR Inhibitor Drugs Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 VEGF & VEGFR Inhibitor Drugs Sales Model
        8.5.2 Sales Channel
        8.5.3 VEGF & VEGFR Inhibitor Drugs Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. VEGF & VEGFR Inhibitor Drugs Market Trends
    Table 2. VEGF & VEGFR Inhibitor Drugs Market Drivers & Opportunity
    Table 3. VEGF & VEGFR Inhibitor Drugs Market Challenges
    Table 4. VEGF & VEGFR Inhibitor Drugs Market Restraints
    Table 5. Global VEGF & VEGFR Inhibitor Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies VEGF & VEGFR Inhibitor Drugs Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies VEGF & VEGFR Inhibitor Drugs Product Type
    Table 9. Key Companies Time to Begin Mass Production of VEGF & VEGFR Inhibitor Drugs
    Table 10. Global VEGF & VEGFR Inhibitor Drugs Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF & VEGFR Inhibitor Drugs as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global VEGF & VEGFR Inhibitor Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global VEGF & VEGFR Inhibitor Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global VEGF & VEGFR Inhibitor Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global VEGF & VEGFR Inhibitor Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Region (2019-2024) & (%)
    Table 27. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions VEGF & VEGFR Inhibitor Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions VEGF & VEGFR Inhibitor Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions VEGF & VEGFR Inhibitor Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 31. Pfizer Basic Information List
    Table 32. Pfizer Description and Business Overview
    Table 33. Pfizer VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
    Table 34. Revenue (US$ Million) in VEGF & VEGFR Inhibitor Drugs Business of Pfizer (2019-2024)
    Table 35. Pfizer Recent Developments
    Table 36. Novartis AG Basic Information List
    Table 37. Novartis AG Description and Business Overview
    Table 38. Novartis AG VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
    Table 39. Revenue (US$ Million) in VEGF & VEGFR Inhibitor Drugs Business of Novartis AG (2019-2024)
    Table 40. Novartis AG Recent Developments
    Table 41. GlaxoSmithKline plc Basic Information List
    Table 42. GlaxoSmithKline plc Description and Business Overview
    Table 43. GlaxoSmithKline plc VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
    Table 44. Revenue (US$ Million) in VEGF & VEGFR Inhibitor Drugs Business of GlaxoSmithKline plc (2019-2024)
    Table 45. GlaxoSmithKline plc Recent Developments
    Table 46. Sanofi Basic Information List
    Table 47. Sanofi Description and Business Overview
    Table 48. Sanofi VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
    Table 49. Revenue (US$ Million) in VEGF & VEGFR Inhibitor Drugs Business of Sanofi (2019-2024)
    Table 50. Sanofi Recent Developments
    Table 51. AstraZeneca plc Basic Information List
    Table 52. AstraZeneca plc Description and Business Overview
    Table 53. AstraZeneca plc VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
    Table 54. Revenue (US$ Million) in VEGF & VEGFR Inhibitor Drugs Business of AstraZeneca plc (2019-2024)
    Table 55. AstraZeneca plc Recent Developments
    Table 56. Bristol-Myers-Squibb Company Basic Information List
    Table 57. Bristol-Myers-Squibb Company Description and Business Overview
    Table 58. Bristol-Myers-Squibb Company VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
    Table 59. Revenue (US$ Million) in VEGF & VEGFR Inhibitor Drugs Business of Bristol-Myers-Squibb Company (2019-2024)
    Table 60. Bristol-Myers-Squibb Company Recent Developments
    Table 61. Genentech, Inc. (Roche) Basic Information List
    Table 62. Genentech, Inc. (Roche) Description and Business Overview
    Table 63. Genentech, Inc. (Roche) VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
    Table 64. Revenue (US$ Million) in VEGF & VEGFR Inhibitor Drugs Business of Genentech, Inc. (Roche) (2019-2024)
    Table 65. Genentech, Inc. (Roche) Recent Developments
    Table 66. Merck & Co., Inc. Basic Information List
    Table 67. Merck & Co., Inc. Description and Business Overview
    Table 68. Merck & Co., Inc. VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
    Table 69. Revenue (US$ Million) in VEGF & VEGFR Inhibitor Drugs Business of Merck & Co., Inc. (2019-2024)
    Table 70. Merck & Co., Inc. Recent Developments
    Table 71. Bayer AG Basic Information List
    Table 72. Bayer AG Description and Business Overview
    Table 73. Bayer AG VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
    Table 74. Revenue (US$ Million) in VEGF & VEGFR Inhibitor Drugs Business of Bayer AG (2019-2024)
    Table 75. Bayer AG Recent Developments
    Table 76. Eli Lilly & Company Basic Information List
    Table 77. Eli Lilly & Company Description and Business Overview
    Table 78. Eli Lilly & Company VEGF & VEGFR Inhibitor Drugs Products, Services and Solutions
    Table 79. Revenue (US$ Million) in VEGF & VEGFR Inhibitor Drugs Business of Eli Lilly & Company (2019-2024)
    Table 80. Eli Lilly & Company Recent Developments
    Table 81. Key Raw Materials Lists
    Table 82. Raw Materials Key Suppliers Lists
    Table 83. VEGF & VEGFR Inhibitor Drugs Downstream Customers
    Table 84. VEGF & VEGFR Inhibitor Drugs Distributors List
    Table 85. Research Programs/Design for This Report
    Table 86. Key Data Information from Secondary Sources
    Table 87. Key Data Information from Primary Sources
    Table 88. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. VEGF & VEGFR Inhibitor Drugs Product Picture
    Figure 2. Global VEGF & VEGFR Inhibitor Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global VEGF & VEGFR Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. VEGF & VEGFR Inhibitor Drugs Report Years Considered
    Figure 5. Global VEGF & VEGFR Inhibitor Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by VEGF & VEGFR Inhibitor Drugs Revenue in 2023
    Figure 7. VEGF & VEGFR Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Tyrosine Kinase Inhibitors Picture
    Figure 9. Monoclonal Antibodies Picture
    Figure 10. Others Picture
    Figure 11. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 12. Global VEGF & VEGFR Inhibitor Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 13. Product Picture of Oncology
    Figure 14. Product Picture of Ophthalmology
    Figure 15. Product Picture of Others
    Figure 16. Global VEGF & VEGFR Inhibitor Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 17. Global VEGF & VEGFR Inhibitor Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 18. North America VEGF & VEGFR Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 19. North America VEGF & VEGFR Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 20. Europe VEGF & VEGFR Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 21. Europe VEGF & VEGFR Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 22. Asia Pacific VEGF & VEGFR Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 23. Asia Pacific VEGF & VEGFR Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 24. South America VEGF & VEGFR Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 25. South America VEGF & VEGFR Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 26. Middle East & Africa VEGF & VEGFR Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 27. Middle East & Africa VEGF & VEGFR Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 28. Key Countries/Regions VEGF & VEGFR Inhibitor Drugs Sales Value (%), (2019-2030)
    Figure 29. United States VEGF & VEGFR Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 30. United States VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 31. United States VEGF & VEGFR Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 32. Europe VEGF & VEGFR Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 33. Europe VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 34. Europe VEGF & VEGFR Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 35. China VEGF & VEGFR Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 36. China VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 37. China VEGF & VEGFR Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 38. Japan VEGF & VEGFR Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 39. Japan VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 40. Japan VEGF & VEGFR Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 41. South Korea VEGF & VEGFR Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 42. South Korea VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 43. South Korea VEGF & VEGFR Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 44. Southeast Asia VEGF & VEGFR Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 45. Southeast Asia VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 46. Southeast Asia VEGF & VEGFR Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 47. India VEGF & VEGFR Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 48. India VEGF & VEGFR Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 49. India VEGF & VEGFR Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 50. VEGF & VEGFR Inhibitor Drugs Industrial Chain
    Figure 51. VEGF & VEGFR Inhibitor Drugs Manufacturing Cost Structure
    Figure 52. Channels of Distribution (Direct Sales, and Distribution)
    Figure 53. Bottom-up and Top-down Approaches for This Report
    Figure 54. Data Triangulation

Description

The global market for VEGF & VEGFR Inhibitor Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for VEGF & VEGFR Inhibitor Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of VEGF & VEGFR Inhibitor Drugs by region & country, by Type, and by Application.

The VEGF & VEGFR Inhibitor Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VEGF & VEGFR Inhibitor Drugs.

Market Segmentation